Photo Credit: Freepik
Information will be updated weekly. If you notice an issue with this data or wish to submit an update, please email BioSpectrum at ankit.kankar@mmactiv.com
Updated 06 November to include new information on vaccine candidates from AstraZeneca/Oxford University, Johnson & Johnson, Bharat Biotech/National Institute of Virology, Pfizer/BioNTech, CureVac, Gamaleya Research Institute, Covaxin and Clover/GSK/Dynavax/Xiamen Innovax Biotech/Sanofi.
| Candidate | Mechanism | Company | Institution | Trial Phase | |
| Ad5-nCoV | Recombinant vaccine (adenovirus type 5 vector) | CanSino Biologics | Tongji Hospital; Wuhan, China | Phase 3 | |
| AZD1222 | Replication-deficient viral vector vaccine (adenovirus from chimpanzees) | AstraZeneca; IQVIA; Serum Institute of India | The University of Oxford, the Jenner Institute | Phase 3 | |
| CoronaVac | Inactivated vaccine (formalin with alum adjuvant) | Sinovac | Sinovac Research and Development Co., Ltd. | Phase 3 | |
| Covaxin | Inactivated vaccine | Bharat Biotech | National Institute of Virology, ICMR | Phase 3 | |
| JNJ-78436735 (formerly Ad26.COV2.S) | Non-replicating viral vector | Johnson & Johnson | Phase 3 | ||
| mRNA-1273 | mRNA-based vaccine | Moderna |
|
Phase 3 | |
| No name announced | Inactivated vaccine | China National Pharmaceutical Group (Sinopharm) |
Wuhan Institute of Biological Products Henan Provincial Center for Disease Control and Prevention |
Phase 3 | |
| NVX-CoV2373 |
|
Novavax | Phase 3 |
